INVESTORS & MEDIA
News Release
Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017
Conference Call Information
To access this call, dial (800) 708-4539 (
About
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led by physician-scientists for nearly 30 years, our unique ability to repeatedly and consistently translate science into medicine has led to six
Regeneron is accelerating and improving the traditional drug development process through its unique VelociSuite® technologies, including VelocImmune® which yields optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Contact Information: |
|
Investor Relations |
Corporate Communications |
|
|
914.847.5126 |
914.847.3407 |
View original content:http://www.prnewswire.com/news-releases/regeneron-to-report-third-quarter-2017-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-8-2017-300534698.html
SOURCE
News Provided by Acquire Media